Innovation, International Growth, and Strong Financials Drive Microvast Holdings, Inc. (MVST)'s Future Growth
A person inspecting a lithium-ion battery that is being recycled.
Innovation, international growth, and strong financials are helping Microvast Holdings, Inc. (NASDAQ:MVST) become a significant player in the battery technology industry.
Through a collaboration with Norway's Evoy, Microvast Holdings, Inc. (NASDAQ:MVST) entered the marine electrification market in 2024 by incorporating its MV-I battery into high-output electric boats, which served as a gateway to specialist industries like aviation and defense.
The momentum continued in January 2025 when Microvast Holdings, Inc. (NASDAQ:MVST) unveiled a breakthrough in True All-Solid-State Battery technology, offering enhanced safety and performance. Citing Microvast's remarkable Q1 2025 results—a 43.2% YoY sales spike, a $61.8 million profit, and growing demand from the EMEA region—H.C. Wainwright reiterated a Buy rating on May 13.
A few days later, on May 19, Microvast Holdings, Inc. (NASDAQ:MVST) demonstrated its innovative edge by showcasing its newest high-energy and fast-charging batteries at the China International Battery Fair. Looking ahead, the company is in an excellent position for future growth, as seen by its shares rising 694% in the last year.
Microvast Holdings, Inc. (NASDAQ:MVST) provides solid-state energy storage and battery solutions for EVs, making it a compelling low-cost investment in the sector. It is included in our list of cheap solid state battery stocks.
While we acknowledge the potential of MVST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 14 Cheap Transportation Stocks to Buy According to Analysts and 10 Cheap Lithium Stocks to Buy According to Hedge Funds.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Pharma interest can plug NIH funding gap: Illumina CEO
Genetic sequencing company Illumina (ILMN) has had a rough few years. It has battled activist investors, faced off with the Federal Trade Commission, and, most recently, agreed to a $9.8 million settlement with the Department of Justice over a cybersecurity breach. To add to the pile: sanctions in China and the Trump administration cutting National Institutes of Health (NIH) funding, which the company relies heavily on for clinical research. The numbers don't lie. The stock is down more than 21% in the past year and sank more than 11% in after-hours trading Thursday after the company reported an earnings miss for the second quarter. The company reported $1.06 billion in revenues compared to expected revenues of $1.05 billion. Adjusted earnings per share came in at $1.19 compared to estimates of $1.01. But CEO Jacob Thaysen told Yahoo Finance he remains positive about the company's near-term growth. Why? Because, in part, pharmaceutical companies can provide a new market. "Now, we're shifting from small things to really big programs. Some of the things making up for the reduction from the NIH is kind of indirect, but pharma is getting more interest in these big programs," he said, noting that 15% of the company is exposed to government research funding. "It's not only about sequencing itself, but really using massive amounts of data ... to really identify new drug targets and understand a disease," Thaysen said. The idea to use patient data to help the pharmaceutical world was also identified by 23andMe, which recently came out of bankruptcy through a nonprofit led by founder Anne Wojcicki. Thaysen said that unlike 23andMe, which he has worked with, his company is not going to pursue drug development on its own. "We have a lot of pharma companies that are very excited to work with us," he said. In addition to genetic testing of patient samples, the company is looking at growing in the preventative side of care with cancer screenings. The oncology business, Thaysen said, will have healthy growth over the next 10 or so years. China China banned importations of the San Diego-based company's sequencing machines earlier this year as part of its retaliatory actions to Trump's tariff war. Thaysen said he is working with regulators to try to reverse that, but "in the meantime, that business is declining, and we are expecting it to be flat." In fact, though China has historically been about 10% of the company's business, it contributed to half of the decline in earnings this past week. "China was never a huge part of Illumina's business. When it was the largest, it was just around 10%. We're down to 5% of the business," Thaysen told Yahoo Finance. But because of the tariff war and China's goals to boost its domestic innovation market, Illumina has faced a setback in its market power there from local competition. "As soon as there is a Chinese alternative that is good enough, then you will see that the Chinese government is pushing for the Chinese population, the Chinese companies to use that technology," Thaysen said. He added that even with the increased competition, China is an appealing market to remain in. Analysts are still waiting to see more progress on Illumina's return to growth. Jefferies analyst Tycho Peterson said in a note to clients that the firm will reiterate its Hold rating until things settle: "While the clinical traction is encouraging, we view clarity on near-term headwinds (A&G, China, Roche) and a path to sustainable HSD growth as key to a more constructive view. Reiterate Hold." Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Stryker lowers expected tariff impact to $175M
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. By the numbers Q2 revenue: $6 billion 11.1% increase year over year Net income: $884 million 7.2% increase year over year Stryker expects a $175 million tariff impact on earnings in 2025, a slight decrease from the $200 million the company forecast in May. Stryker joins several medical device companies that have slashed tariff expectations, with several firms, including Johnson & Johnson and Boston Scientific, cutting the expected tariff hit by as much as half. Stryker CFO Preston Wells said Thursday on an earnings call that the changes were a result of the U.S. and China agreeing to significantly reduce levies. However, Stryker did not cut its forecast by as much as other companies because the recent trade agreement with the European Union, which set a tariff rate of 15%, was more than the 10% Stryker had included in its previous model. CEO Kevin Lobo said Stryker was impacted less than other companies due to its manufacturing footprint in Europe and having less of a presence in China than other medtech companies. Raised earnings forecast Stryker raised its financial forecast for the year, now expecting organic sales growth in a range of 9.5% to 10%, from a previous range of 8.5% to 9.5%. The company also raised its expectations for adjusted earnings per share by about 20 cents. Lobo said the update was driven by continued procedural strength, including implants, and demand for capital equipment. Wells said initiatives Stryker started during the COVID-19 pandemic, such as pricing and manufacturing efficiency, have helped drive margin improvements. Robot update Stryker shared an update on planned launches for the company's robots. In March, the company unveiled its latest orthopedic robot, the Mako 4. The Food and Drug Administration cleared the new system, but Stryker has not yet rolled out the robot globally, Lobo said. The company has new hip revision and spine surgery applications that are only available on Mako 4. Stryker's shoulder surgery application is currently on its Mako 3 robot, and is in the process of migrating to the newer robot, Lobo said. Because of that, the feature is still in a limited launch until next year. Stryker reported a record quarter for Mako installations, although the company did not disclose the number of robots. The company reached a milestone of 2 million robotic procedures performed with Mako during the second quarter. Recommended Reading Stryker expects $200M tariff hit, lowers earnings forecast Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Lufax Holding Ltd (LU) Sells $64M in Bad Loans to Cut Credit Risk, Stabilize Outlook
We recently compiled a list of the 10 Best Low Cost Stocks To Buy Under $50. Lufax Holding Ltd stands fourth on our list. Lufax Holding Ltd (NYSE:LU), a leading Chinese fintech firm serving small and micro businesses, is undergoing strategic shifts to navigate a challenging market in 2025. A key recent development was the sale of non-performing loans (NPLs) through its subsidiary, Ping An Consumer Finance. The transaction involved offloading 469 million yuan in NPLs for 36.44 million yuan to Sh China Merch Ping An Asset Management. This move reduced credit risk and supported a drop in the company's loan portfolio by 18%, helping stabilize investor sentiment amid asset quality concerns. In addition to asset optimization, Lufax Holding Ltd (NYSE:LU) is focusing on digital transformation through new partnerships and AI-driven innovation. These efforts aim to boost operational efficiency and profitability while enhancing its competitive edge in a crowded fintech market. The business is also pursuing cost-cutting measures as part of a broader strategy to improve earnings. Despite these positive steps, cheap stocks to buy like Lufax Holding Ltd (NYSE:LU) saw sharp declines in late July, dropping over 11% and 12% on back-to-back days. The sell-off reflected investor concerns over limited near-term catalysts and persistent pressure from traditional banks. An individual using a laptop to access the fintech platform to manage their finances. Looking ahead, the corporation plans to continue managing credit risk proactively, expand its digital offerings, and pursue strategic partnerships. These efforts are expected to support earnings growth and may enable the resumption of dividends by the end of the 2025 fiscal year. While we acknowledge the potential of LU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
